CareTrust REIT is the standout laggard in the healthcare REIT space this week, and the short interest data tells you exactly why the market is paying attention.
Short sellers have dramatically rebuilt their position in CTRE. Short interest jumped 55% in a single week to 8.6% of the free float — and over 30 days the increase is a striking 153%. The move appears concentrated: looking at the daily history, shorts essentially doubled around June 9, leaping from roughly 12-13 million shares to 19 million in the space of two sessions. That kind of step-change typically reflects a deliberate positioning decision, not a slow bleed. The ORTEX short score crossed from the mid-40s to the mid-50s at precisely the same moment, confirming the shift in sentiment.
The borrow market, however, is nowhere near stressed — and that contrast is the key to reading this setup correctly. Availability is running at around 678%, meaning there are roughly seven shares available to lend for every one currently borrowed. That is comfortably within a normal range and well above the 52-week tightest point of 509%. Cost to borrow has nudged up 32% on the week but remains at just 0.56% — essentially free money for a short position. This is not a squeeze setup. Shorts are building a fresh directional trade, not fighting for scarce inventory. Options positioning lends some support to that cautious read: the put/call ratio is running at 0.61, about 1.6 standard deviations above its 20-day average of 0.49, signalling incrementally more defensive hedging than usual. It is not an extreme reading, but it aligns with the short interest direction.
The Street remains constructively positioned, which makes the short buildup more interesting. Raymond James reinstated coverage this week with an Outperform rating and a $43 target. BMO Capital raised its target to $47 from $46 on June 15, also maintaining Outperform. Wells Fargo lifted its target to $47 from $42 two weeks ago. The analyst consensus mean target is $45.50 against a current price of $37.03 — roughly 23% implied upside. Bulls point to CTRE's triple-net lease structure, balance sheet discipline, and the portfolio diversification across skilled nursing and seniors housing as durable earnings anchors. Bears flag revenue concentration risk around a single large tenant, timing headwinds on new investments, and rising G&A costs eating into margins. EPS momentum ranks in the 95th percentile on a 30-day basis, suggesting upgrades are still running through the model — which explains why analysts are comfortable lifting targets even as the stock pulls back. The PE multiple has compressed roughly four turns over the past month, from around 25x to 20.8x.
The peer divergence sharpens the picture. WELL gained 3.3% on the week. VTR added 1.7%. LTC rose 0.7%. Even SBRA — down 1.8% — largely tracked CTRE's loss. CTRE's 1.8% weekly decline is not dramatic in isolation, but it sits on top of a 10% decline over the past month while most healthcare REIT peers have traded flat to higher over the same period. Something specific is weighing on CTRE that is not a broad sector story. Institutional ownership remains concentrated — BlackRock holds 15.2% and Vanguard entities together account for over 12% — so any index rebalancing or active rotation out of those large blocks would have an outsized effect on the float.
Insider data is stale as of January 30, so no fresh signal there. The most recent trades on record were coordinated open-market sells by the CEO, CIO, and Chief Accounting Officer at $37.34 — almost exactly the current price — though these appeared consistent with planned selling programs rather than discretionary exits.
The next scheduled catalyst is Q2 earnings on August 6. With short interest now at a multi-month high, analyst targets clustered well above the current price, and peers holding up better on the week, the tension between the short community's conviction and the Street's continued bullishness is what to watch as the stock approaches that date.
See the live data behind this article on ORTEX.
Open CTRE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
